tbuckley/cabot-search huggingface dataset:
Ribosomal Protein L19 Is a Prognostic Marker for Human Prostate Cancer
Authors: Alix Bee, Youqianq Ke, Shiva Forootan, Ke Lin, Carol Beesley, Sharon E. Forrest, Christopher S. Foster
Journal: Clinical Cancer Research (2006)

Abstract Microquantity differential display analysis of gene expression profiles between benign (PNT2) and malignant (PC3M) human prostate cell lines identified the gene encoding ribosomal protein L19 (RPL19) to be overexpressed in the malignant cells. Northern blot hybridization analysis done on a wide range of human cell lines and tissues confirmed the level of RPL19 mRNA to be 5-fold higher in malignant cell lines and 8-fold higher in malignant tissues, when compared with their benign counterparts. Analysis of RPL19 mRNA expression by in situ hybridization revealed a significant increase of RPL19 expression in a substantial number of prostate cancers. All of the eight normal prostatic tissues were unstained (100%). Of 32 benign prostatic hyperplasia (BPH) tissues, 15 (46.9%) were unstained, 9 (28.1%) stained weakly, and 8 (25%) stained moderately. Among 87 carcinomas, only 7 (8.1%) were unstained, whereas 22 (25.2%) stained weakly, 21 (24.1%) stained moderately, and 37 (42.61%) stained strongly. The intensity of staining of the malignant specimens was significantly higher than that of normal and BPH specimens (χ2: n = 127, P &amp;lt; 0.001). Gleason scores of the carcinomas correlated with RPL19 expression (χ2: n = 87, P &amp;lt; 0.001). Kaplan-Meier survival analysis confirmed increased RPL19 expression to be highly predictive of shorter patient survival (P &amp;lt; 0.05), revealing RPL19 to be a sensitive predictor of prostate cancer progression. Expression of this protein could be a valuable marker in prostate cancer diagnosis and patient management.
MULTICENTER, PROSPECTIVE, RANDOMIZED, SINGLE BLIND, CONSECUTIVE ENROLLMENT EVALUATION A NOVOLIMUS-ELUTING CORONARY STENT SYSTEM WITH BIOABSORBABLE POLYMER COMPARED TO A ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM: 6-MONTH ANGIOGRAPHIC AND IVUS RESULTS AND 24- MONTH CLINICAL: THE EXCELLA BD STUDY
Authors: Alexandre Abizaid, Joachim Schofer, Roberto Botelho, Stefan Verheye, Ricardo Costa, Luiz Fernando Tanajura, Lynn Morrison, Sara Toyloy, Peter Fitzgerald
Journal: Journal of the American College of Cardiology (2013)
A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients
Authors: I. Bairati, F. Meyer, M. Gelinas, A. Fortin, A. Nabid, F. Brochet, J.-P. Mercier, B. Tetu, F. Harel, B. Masse, E. Vigneault, S. Vass, P. del Vecchio, J. Roy
Journal: JNCI Journal of the National Cancer Institute (2005)

Background: Although low dietary intakes of antioxidant vitamins and minerals have been associated with higher risks of cancer, results of trials testing antioxidant supplementation for cancer chemoprevention have been equivocal. We assessed whether supplementation with antioxidant vitamins could reduce the incidence of second primary cancers among patients with head and neck cancer. Methods: We conducted a multicenter, double-blind, placebo-controlled, randomized chemoprevention trial among 540 patients with stage I or II head and neck cancer treated by radiation therapy between October 1, 1994, and June 6, 2000. Supplementation with α-tocopherol (400 IU/day) and β-carotene (30 mg/day) or placebo began on the first day of radiation therapy and continued for 3 years after the end of radiation therapy. In the course of the trial, β-carotene supplementation was discontinued after 156 patients had enrolled because of ethical concerns. The remaining patients received α-tocopherol or placebo only. Survival was evaluated by Kaplan-Meier analysis. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. Results: After a median follow-up of 52 months, second primary cancers and recurrences of the first tumor were diagnosed in 113 and 119 participants, respectively. The effect of supplementation on the incidence of second primary cancers varied over time. Compared with patients receiving placebo, patients receiving α-tocopherol supplements had a higher rate of second primary cancers during the supplementation period (HR = 2.88, 95% CI = 1.56 to 5.31) but a lower rate after supplementation was discontinued (HR = 0.41, 95% CI = 0.16 to 1.03). Similarly, the rate of having a recurrence or second primary cancer was higher during (HR = 1.86, 95% CI = 1.27 to 2.72) but lower after (HR = 0.71, 95% CI = 0.33 to 1.53) supplementation with α-tocopherol. The proportion of participants free of second primary cancer overall after 8 years of follow-up was similar in both arms. Conclusions: α-Tocopherol supplementation produced unexpected adverse effects on the occurrence of second primary cancers and on cancer-free survival.
Infliximab for hidradenitis suppurativa
Authors: T.P. Sullivan, E. Welsh, F.A. Kerdel, A.E. Burdick, R.S. Kirsner
Journal: British Journal of Dermatology (2003)

Hidradenitis suppurativa (HS) is a chronic disease characterized by significant morbidity. Current medical therapies are only minimally effective at treating the disease. Infliximab is a chimeric monoclonal antibody with high affinity for tumour necrosis factor (TNF)-alpha. TNF-alpha is known to induce proinflammatory cytokines and may play an important role in the therapy of a number of disparate inflammatory disorders. Infliximab has shown promise for the therapy of rheumatoid arthritis and psoriasis.Retrospectively to evaluate the effectiveness of infliximab for the treatment of HS.A retrospective chart review was performed for patients who received infliximab at the University of Miami Department of Dermatology. Patients were contacted and asked retrospectively to rate their disease activity immediately prior to and after therapy.Patients' self-reported disease activity scores were significantly decreased (P = 0.0001, paired t-test) following infliximab infusion. This correlated with physician-observed clinical improvement.Infliximab is a promising agent for the treatment of HS. These initial results suggest that infliximab is associated with objective and subjective improvement in HS. Further controlled studies of the efficacy of infliximab and its effect on the course of the disease are warranted.
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
Authors: Giovanni Palladini, Francesca Lavatelli, Paola Russo, Stefano Perlini, Vittorio Perfetti, Tiziana Bosoni, Laura Obici, Arthur R. Bradwell, GianVico Melzi D'Eril, Roberto Fogari, Remigio Moratti, Giampaolo Merlini
Journal: Blood (2006)
Importance of Health Information Technology, Electronic Health Records, and Continuously Aggregating Data to Comparative Effectiveness Research and Learning Health Care
Authors: Benjamin J. Miriovsky, Lawrence N. Shulman, Amy P. Abernethy
Journal: Journal of Clinical Oncology (2012)

Rapidly accumulating clinical information can support cancer care and discovery. Future success depends on information management, access, use, and reuse. Electronic health records (EHRs) are highlighted as a critical component of evidence development and implementation, but to fully harness the potential of EHRs, they need to be more than electronic renderings of the traditional paper medical chart. Clinical informatics and structured accessible secure data captured through EHR systems provide mechanisms through which EHRs can facilitate comparative effectiveness research (CER). Use of large linked administrative databases to answer comparative questions is an early version of informatics-enabled CER familiar to oncologists. An updated version of informatics-enabled CER relies on EHR-derived structured data linked with supplemental information to provide patient-level information that can be aggregated and analyzed to support hypothesis generation, comparative assessment, and personalized care. As implementation of EHRs continues to expand, electronic databases containing information collected via EHRs will continuously aggregate; aggregating data enhanced with real-time analytics can provide point-of-care evidence to oncologists, tailored to patient-level characteristics. The system learns when clinical care informs research, and insights derived from research are reinvested in care. Challenges must be overcome, including interoperability, standardization, access, and development of real-time analytics.
Lysophosphatidic Acid Receptors LPA <sub>1</sub> and LPA <sub>3</sub> Promote CXCL12-Mediated Smooth Muscle Progenitor Cell Recruitment in Neointima Formation
Authors: Pallavi Subramanian, Ela Karshovska, Patricia Reinhard, Remco T.A. Megens, Zhe Zhou, Shamima Akhtar, Uwe Schumann, Xiaofeng Li, Marc van Zandvoort, Christian Ludin, Christian Weber, Andreas Schober
Journal: Circulation Research (2010)

The chemokine CXCL12 (CXC motif ligand 12) and its receptor CXCR 4 (CXC motif receptor 4) direct the recruitment of smooth muscle progenitor cells (SPCs) in neointima formation after vascular injury. Lysophosphatidic acid (LPA) induces CXCL12 and neointimal accumulation of smooth muscle cells (SMCs) in uninjured arteries. Thus, we hypothesize that LPA may regulate CXCL12-mediated vascular remodelling.We evaluated the role of LPA receptors in initiating CXCL12-dependent vascular repair by SPCs.Wire-induced carotid injury was performed in apolipoprotein E(-/-) mice on western-type diet. LPA receptor expression was studied by immunostaining and quantitative RT-PCR. LPA receptors LPA(1) and LPA(3) were detected in the media of uninjured arteries and in the injury-induced neointima. LPA(3) mRNA was upregulated and LPA(1) mRNA downregulated at one week after injury. The LPA(1/3) antagonist Ki16425 inhibited neointima formation by 71% and reduced both relative neointimal SMCs and the macrophage content. Additionally, neointimal hypoxia-inducible factor-1alpha and CXCL12 expression, the injury-induced peripheral stem cell antigen-1 (Sca-1)(+)/Lin(-) SPC mobilization, and the neointimal recruitment of Sca-1(+)SMCs were inhibited by Ki16425. In wild type mice, LPA20:4 increased CXCL12 and hypoxia-inducible factor-1alpha expression in carotid arteries as early as 1 day following short-term endoluminal incubation. LPA20:4-induced SPC mobilization and neointima formation were blocked by Ki16425, LPA(1)- and LPA(3)-specific small interfering (si)RNA, and the CXCR4 antagonist POL5551. Ki16425 reduced LPA20:4-mediated neointimal recruitment of SPC as demonstrated by 2-photon microscopy in bone marrow chimeric mice after repopulation with SM22-LacZ transgenic, hematopoietic cells. Moreover, POL5551 decreased the neointimal accumulation of CXCR4(+) SMCs.LPA(1) and LPA(3) promote neointima formation through activation of CXCL12-mediated mobilization and recruitment of SPCs.
Evaluation of Plasma, Metaraminol, and Hydrocortisone in Experimental Endotoxin Shock
Authors: WESLEY W. SPINK, JAMES VICK
Journal: Circulation Research (1961)

An experimental model of canine endotoxin shock was employed for evaluating therapeutic agents that are used in the management of peripheral vascular collapse. An important feature of the present study was that an agent or agents were not administered until hypotension and oligulria were present. Progressive endotoxin shock was not reversed by the infusion of large amounts of canine plasma. Large doses of hydrocortisone did not prevent a lethal outcome. Even though the blood pressure was stabilized near normotensive levels with the vasopressor drug, metaraminol, progressive shock occurred. The most significant finding was that lethal endotoxin shock was prevented in six of the 10 animals studied by the simultaneous use of hydrocortisone and metaraminol. Only one-eighth the amount of metaraminol was necessary to maintain normotensive levels of blood pressure if a large dose of hydrocortisone was administered before the infusion of the pressor drug.
Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography findings
Authors: S. Kuroishi, Y. Nakamura, H. Hayakawa, M. Shirai, Y. Nakano, K. Yasuda, T. Suda, H. Nakamura, K. Chida
Journal: European Respiratory Journal (2008)

To evaluate the prognostic implications of computed tomography (CT) findings in assessing responses to treatment in <i>Mycobacterium avium</i> complex (MAC) pulmonary disease without underlying lung disease, high-resolution (HR)CT findings were correlated based on the results of sputum conversion after anti-MAC therapy. A total of 59 patients underwent HRCT before treatment and the therapeutic efficacy was evaluated by the results of sputum conversion. Atelectasis, cavities and pleural thickening on HRCT were significantly more frequent and extensive among patients in the sputum nonconverted group than among those in the converted group. Furthermore, bronchiectasis was also significantly more extensive among patients in the nonconverted group, even though there was no significant difference in frequency between these two groups. These results suggest that high-resolution computed tomography findings are good predictors of response to treatment in <i>Mycobacterium avium</i> complex pulmonary disease.
Risk of injury on third-generation artificial turf in Norwegian professional football
Authors: John Bjørneboe, Roald Bahr, Thor Einar Andersen
Journal: British Journal of Sports Medicine (2010)

Background Artificial turf is used extensively in both recreational and elite football in areas with difficult climatic conditions. Objective To compare the risk for acute injuries between natural grass (NG) and third-generation artificial turf (3GAT) in male professional football. Study design Prospective cohort study. Methods All injuries sustained by players with a first-team contract were recorded by the medical staff of each club, from the 2004 throughout the 2007 season. An injury was registered if the player was unable to take fully part in football activity or match play. Results A total of 668 match injuries, 526 on grass and 142 on artificial turf, were recorded. The overall acute match injury incidence was 17.1 (95% CI 15.8 to 18.4) per 1000 match hours; 17.0 (95% CI 15.6 to 18.5) on grass and 17.6 (95% CI 14.7 to 20.5) on artificial turf. Correspondingly, the incidence for training injuries was 1.8 (95% CI 1.6 to 2.0); 1.8 (95% CI 1.5 to 2.0) on grass and 1.9 (95% CI 1.5 to 2.2) on artificial turf respectively. No significant difference was observed in injury location, type or severity between turf types. Conclusion No significant differences were detected in injury rate or pattern between 3GAT and NG in Norwegian male professional football.
Protection of Human Subjects in Intervention Research for Suicidal Behavior
Authors: Maria A. Oquendo, Barbara Stanley, Steven P. Ellis, J. John Mann
Journal: American Journal of Psychiatry (2004)

OBJECTIVE: Three domains of ethical conduct outlined in the U.S. Food and Drug Administration’s 1998 Belmont Report on protection of human research subjects—respect for persons, beneficence, and justice—have posed specific dilemmas in the design of intervention studies for suicidal behavior. These issues include questions about suicidal patients’ capacity to provide informed consent, the risk of some lethal outcomes, the possibility of imminent suicide risk associated with patients’ right to discontinue the study treatment, and the need for a higher level of monitoring of suicidal patients. The authors examine these and other issues and discuss ways they can be addressed in research design. METHOD: To illustrate solutions to these bioethical tensions, the authors describe the design of a randomized, controlled trial of pharmacotherapy for suicidal behavior in bipolar disorder. RESULTS: Using surrogate outcome measures, allowing prescription of rescue medications, integrating psychosocial interventions, and providing close clinical monitoring enable researchers to conduct research on suicidal behavior while maximizing adherence to the ethical recommendations outlined in the Belmont Report. Alternative study designs, such as add-on trials, in which the study treatment or placebo is added on to known effective treatment, may also be used in research on suicidal behavior. CONCLUSIONS: It is possible to design a randomized, controlled trial that minimizes the risk of morbidity and mortality for suicidal patients with bipolar disorder, but deliberation is required to address the bioethical tensions that arise.
hTERT expression and prognosis in B-chronic lymphocytic leukemia
Authors: A. Tchirkov, C. Chaleteix, C. Magnac, Y. Vasconcelos, F. Davi, A. Michel, F. Kwiatkowski, O. Tournilhac, G. Dighiero, P. Travade
Journal: Annals of Oncology (2004)
Hepatocyte expression of serum response factor is essential for liver function, hepatocyte proliferation and survival, and postnatal body growth in mice
Authors: Kai Sun, Michele A. Battle, Ravi P. Misra, Stephen A. Duncan
Journal: Hepatology (2009)

Serum response factor (SRF) is a transcription factor that binds to a CarG box motif within the serum response element of genes that are expressed in response to mitogens. SRF plays essential roles in muscle and nervous system development; however, little is known about the role of SRF during liver growth and function. To examine the function of SRF in the liver, we generated mice in which the Srf gene was specifically disrupted in hepatocytes. The survival of mice lacking hepatic SRF activity was lower than that of control mice; moreover, surviving mutant mice had lower blood glucose and triglyceride levels compared with control mice. In addition, SrfloxP/loxPAlfpCre mice were smaller and had severely depressed levels of serum insulin-like growth factor 1 (IGF-1). Srf-deficient livers were also smaller than control livers, and liver cell proliferation and viability were compromised. Gene array analysis of SRF depleted livers revealed a reduction in many messenger RNAs, including those encoding components of the growth hormone/IGF-1 pathway, cyclins, several metabolic regulators, and cytochrome p450 enzymes. Conclusion: SRF is essential for hepatocyte proliferation and survival, liver function, and control of postnatal body growth by regulating hepatocyte gene expression. (HEPATOLOGY 2009.)
ASSESSMENT OF TECHNICAL CHANGES DURING SWIMMING PERFORMANCE IN TRAINED JUNIOR SWIMMERS: Table 1
Authors: DT Archer, L Berry, S Dixon, R Hogg
Journal: British Journal of Sports Medicine (2013)

Inertial sensor technology is a reliable technique to provide measures such as acceleration and deceleration in laboratory and field conditions (Boyd et al . IJSPP 2011;6:311–321). In competitive pool swimming, the athlete's goal is to adopt an efficient technique to maximise propulsion and minimise drag and deceleration (Barbosa et al . JSMS 2010;13:262–269). The aim of the present study was to assess technical aspects of swimming performance using the inertial sensors contained within a team sports GPS system. Nine regional and national level swimmers, three male and six females aged 13±3 years, height 1.63±0.74 m and body mass 56.5±10.0 kg performed three maximal 800-m freestyle time trials on three occasions in a 25 m pool, each separated by seven days. Following a 400-m standardised warm up, swimmers started the time trial with a push off from the wall. A tri-axial accelerometer and gyroscope, contained within the Catapult Minimax S4 Athlete Monitoring System was used to assess split times, Player Load, stroke rate and rate of body roll at 100 Hz. Subject's mean 800-m time was 727.8±27.2 s and did not differ between trials, resulting in a coefficient of variation (CV) of 3±1% between races. The greatest swim velocities occurred in the initial 25 m in each trial. Player Load was greatest and the rate of body roll tended to be lowest on this lap. Mean Player Load per stroke, stroke rate and rate of body roll did not differ between trials (P&gt;0.05) and mean CV values varied between 4 and 7% across the 32 laps, indicating low between-lap variability for these parameters. Table 1 Player Load and rate of body roll during three swimming time trials Mean±SD Player Load (au) Mean±SD rate of body roll (°.s -1 ) Trial 1 0.34±0.06 130±30 Trial 2 0.30±0.04 123±28 Trial 3 0.31±0.05 121±33 In conclusion, the Catapult Minimax S4 system can be used to collect technical data during swim performance, providing measures of within- and between- lap and race variability.
The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice.
Authors: K Hayakawa, R R Hardy, D R Parks, L A Herzenberg
Journal: The Journal of Experimental Medicine (1983)

A small subpopulation of normal murine splenic B cells carrying all of the classic B cells markers (IgM, IgD, Ia, and ThB) also carries Ly-1, one of the major T cell surface molecules. This "Ly-1 B" subpopulation (identified and characterized by multiparameter FACS analyses) consists of relatively large, high IgM/low-IgD/low-Ly-1 lymphocytes that represent approximately 2% of the spleen cells in normal animals and, generally, 5-10% of spleen cells in NZB mice. Ly-1 B are clearly detectable in all normal mouse strains tested as well as NZB, CBA/N, other X-id mice and nude (nu/nu) mice. They are found primarily in the spleen; are either absent or very poorly represented in lymph node, bone marrow, and thymus; appear early during ontogeny, and comprise about a third of the small number of lymphocytes present in 5-d-old mice. NZB and (NZB x NZW)F1 mice have more Ly-1 B than all other strains and, furthermore, have a unique Ly-1 B population that secretes IgM when cultured under usual conditions in the absence of added antigen. The IgM secretion by these Ly-1 B cells accounts for the previously reported "spontaneous" IgM secretion by NZB spleen cells in culture. Studies with FACS-sorted cells show that the presence of Ly-1 on these IgM-secreting cells distinguishes them from the (Ly-1 negative) IgM-secreting "direct" plaque-forming cells generated in NZB mice after stimulation with sheep erythrocytes.